For U.S. Healthcare Professionals Only
Prescribing Information
Important Safety Information  |   Prescribing Information For U.S. Healthcare Professionals Only

Important Safety Information: SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One. View More

A A A

MySynvisc

MySynvisc is an innovative inventory management and benefit verification service managed exclusively by Careform for Synvisc® and Synvisc-One®.*

Activate your MySynvisc account: Choose benefit verification, inventory management or both. Call 1-844-MYSYNVISC Monday through Friday, 8 a.m. to 7 p.m., excluding major holidays, or fill out this form, and our team at Careform will contact you.


Benefit Verification

Careform stands behind the accuracy of results provided through the program, MySynviscTMBV. If a claim is denied as a result of an error by MySynviscTMBV, the practice will be eligible for reimbursement up to their SYNVISC and/or Synvisc-One product cost.



MySynviscTMBV is a portal to help you:

  • Verify insurance benefits (medical and pharmacy)
  • Obtain prior authorizations
  • Coordinate specialty pharmacy fulfillment
  • Track the progress of each case at any time
  • Electronically submit prior authorization forms
  • Electronically submit specialty pharmacy submissions

On average, 98% of patient cases that were
NOT cancelled received coverage.


Print the MySynvisc Benefit Verification Fact Sheet

*Patient information is exclusively managed, hosted and solely accessible by Careform and respective doctors’ offices.

If submitted by 1 p.m. Eastern Time and no prior authorization or additional information required.

Data on file. 


Inventory Management




MySynviscTM Inventory Management allows you to:

  • Always see on-hand inventory, shipped products and outstanding orders
  • Record SYNVISC and Synvisc-One dosages, batch numbers and expiration dates using the bar code scanner
  • Assign product quantities to specific physicians
  • Set reordering limits to monitor inventory levels


Print the MySynvisc Inventory Management Fact Sheet

Indication

SYNVISC® (hylan G-F 20) and Synvisc-One® (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information

SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One.

Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Do not inject SYNVISC or Synvisc-One extraarticularly, into the synovial tissues, into the fat pad or joint capsule, or intravascularly.

The safety and efficacy of Synvisc-One in locations other than the knee, or for conditions other than osteoarthritis, or in combination with other intra-articular injectables, or in severely inflamed knee joints have not been established. Use caution when injecting SYNVISC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of lymphatic or venous stasis in the leg to be treated; or who have severe inflammation in the knee to be treated. Remove any synovial fluid or effusion before injecting SYNVISC or Synvisc-One. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc-One have not been established in children (≤21 years old) or in pregnant or lactating women. Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment.

For SYNVISC

In clinical trials, the most commonly reported adverse events were transient pain, swelling, and or joint effusion in the injected knee. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for SYNVISC

For Synvisc-One

The most commonly reported adverse events were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Full Prescribing Information for Synvisc-One